CRISPR Therapeutics Stock Wins a Buy Rating: What You Need to Know
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one high-profile Wall Street pick and putting it under the microscope...
CRISPR could change the world -- and Piper Jaffray is placing its bet on the company that took the name of this revolutionary gene-editing tool for its own: CRISPR Therapeutics (NASDAQ: CRSP).
This morning, Piper announced it is initiating coverage of Swiss genetics company CRISPR Therapeutics with an overweight rating and a $30 price target (shares currently cost less than $20). It's far from a sure bet, but for investors who won't balk at a big gamble on a potentially even bigger payday, it's a bet that could pay off.
Source: Fool.com
CRISPR Therapeutics AG Stock
With 0 Sell predictions and 2 Buy predictions the community sentiment towards the CRISPR Therapeutics AG stock is not clear.
Based on the current price of 41.4 € the target price of 200 € shows a potential of 383.09% for CRISPR Therapeutics AG which would more than double the current price.
